The EBOVAC2 Consortium brings together Crucell Holland B.V., one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) as Project Leader and Inserm as Coordinator with its leading expertise in the coordination of large clinical trials in Europe and Africa (ISO 9001:2008 certification), coordination of vaccine and immune intervention trials (especially in HIV) and Immune monitoring in HIV infections and other diseases as well as Inserm’s key infrastructures notably EUCLID (Trials Services Platform & Development) and the Jean Mérieux BSL4 Laboratory possessing the highest level of international biological safety standards to ensure that the EBOVAC vaccine regimen can demonstrate efficacy in non-human primates.

lab1© Janssen

The London School of Hygiene & Tropical Medicine has played key roles in many vaccine trials conducted in developing countries ranging from phase 1 to phase 2b large scale safety and immunogenicity study. LSHTM is well qualified to support many aspects of multidisciplinary trials of Ebola vaccines. The University of Oxford group has been running vaccine clinical trials with children and adults in the UK and will bring its expertise to EBOVAC2 for Phase 2 studies.       

EBOVAC2’s African partner - the CENTRE MURAZ- will ensure strong African involvement in the clinical trials and associated activities notably communication and capacity building. Inserm Transfert, with its dedicated and professional European Project Management and IPR management teams, will ensure that EBOVAC2 produces high quality results, adheres to all contractual expectations and communicates efficiently to all stakeholders.

 

 

News

  • 12 September 2017

    Clinical Trial Training - Bobo Dioulasso, BURKINA FASO, 7-10 November, 2017 Registration - Enregistrement

  • 12 September 2017

    The 3rd EBOVAC1/2 Annual meeting will be held in Nairobi, Kenya 28-30 November 2017. Participants include consortium members and representatives of sites where the project clinical trials are being carried out.

  • 27 June 2017

    The 2nd EBOVAC2 newsletter June 2017 is now available here!

  • 15 May 2017

    Based on final Phase 1 data published in JAMA: The Journal of the American Medical Association, the prime-boost Ebola vaccine regimen induced an antibody response that persisted in 100 percent of healthy volunteers to at least 1 year following vaccination. The results are from the EBOVAC1 study EBL1001 conducted by the Oxford Vaccine Group in the UK.

  • 15 May 2017

    Victoria Derbyshire reporter Catrin Nye went to visit the Oxford Vaccine Group looking for volunteers who participated in the EBL2001 study. Prof. Andrew Pollard (Professor of Paediatric Infection and Immunity and Oxford Vaccine Group PI for EBOVAC1 and EBOVAC2 ) and study volunteers were interviewed.Watch here : http://www.bbc.co.uk/news/uk-39202974

  • 13 November 2016

    The joint EBOVAC1 and EBOVAC2 annual meeting took place in Windsor, UK from 14-16 November 2016.

More news
  • Ebola: background

    What is Ebola?

  • Phase 2 trials

    Find out more about EBOVAC2 trials

  • Work programme

    EBOVAC2 is organised into 6 workpackages (WP)

  • Ebola+ programme

    Contributes to efforts to tackle a wide range of challenges in Ebola research